,102 Despite the considerable advancement of CDK4/6 inhibitors in the treatment of BC, tumor resistance to CDK4/6 inhibitors has been globally reported,103,104 and there is an urgent need to explore their specific mechanisms. This evidence concerns the gene CDK4 and breast cancer.